Emcor vs Legence
EME and LGN side by side, both in industrials. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EME and LGN compare
Emcor is the larger company, worth 7.1 times as much as Legence ($30.0B against $4.2B).
Legence grew revenue faster over the last twelve months (69.2% versus 22.1% for Emcor).
Emcor keeps more of each dollar of sales as profit, with a net margin of 7.8% compared with −1.2% at Legence.
Emcor pays a dividend yielding 0.24%; Legence does not pay one.
Emcor scores higher on the StockData Score (24 against 6 for Legence), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EME | LGN |
|---|---|---|
| Size and price | ||
| Market cap | $30.0B | $4.2B |
| Share price | $679.55 | $38.83 |
| Change, 1 year | −12.5% | −6.5% |
| Change, 5 years | 414% | – |
| Beta (5Y) | 1.09 | 2.19 |
| Employees | 44K | 7,000 |
| StockData Score | ||
| Total score | 24 (better) | 6 |
| Valuation score | 3 (better) | 0 |
| Growth score | 5 (better) | 2 |
| Performance score | 6 (better) | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 19.6× | – |
| P/S | 1.5× | 1.1× (better) |
| P/B | 7.0× | 7.0× (better) |
| EV/EBITDA | 14.1× (better) | 34.7× |
| P/FCF | 20.2× | 13.0× (better) |
| PEG | 0.38 | – |
| FCF yield | 4.9% | 7.7% (better) |
| Fair value | $658.47 | $10.53 |
| Margin of safety | −3.2% (better) | −269% |
| Growth | ||
| Revenue growth (TTM) | 22.1% | 69.2% (better) |
| Revenue growth, 5Y average | 14.1% | – |
| Net income growth (TTM) | 36.6% | – |
| EPS growth (TTM) | 39.2% | – |
| EPS growth, 5Y average | 63.7% | – |
| Profitability | ||
| Gross margin | 19.6% (better) | 18.7% |
| Operating margin | 10.4% (better) | 0.79% |
| Net margin | 7.8% (better) | −1.2% |
| FCF margin | 7.5% | 8.6% (better) |
| Return on equity | 40.6% (better) | −7.5% |
| Return on invested capital | 49.5% (better) | 1.7% |
| Financial health | ||
| Debt / equity | 0.00 | 1.72 (better) |
| Net debt / EBITDA | – | 4.85 |
| Interest coverage | – | 0.4× |
| Current ratio | 1.17 | 1.35 (better) |
| Altman Z-score | 5.95 (better) | 1.95 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 0.24% | – |
| Payout ratio | 4.2% | – |
| Years of dividend growth | 5 | – |
| Dividend growth, 5Y average | 25.6% | – |
| Buyback yield | 2.0% | – |
| Shareholder yield | 2.3% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 94.0% | 79.0% |
| Held by insiders | 0.73% | 47.1% |
| Insider net buying, 12 months | −$40.8M (better) | −$2.5B |
| Short interest, % of float | 1.7% | 6.3% |
Go deeper
- EME stock overview
- EME income statement
- EME valuation and score
- LGN stock overview
- LGN income statement
- LGN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.